How to Lose Belly Fat: NHS-Backed Advice

How to lose belly fat is one of the most searched health questions in the UK, and for good reason: excess abdominal fat is linked to serious conditions including type 2 diabetes, cardiovascular disease and metabolic syndrome. Yet belly fat is notoriously difficult to shift, partly because a significant proportion of it is visceral fat stored deep around the organs. This article explains why belly fat behaves differently, what NHS and NICE guidance recommends, which lifestyle changes have the strongest evidence, and when medical treatment may be appropriate.

Why is belly fat harder to lose than fat elsewhere on the body?

Belly fat is harder to lose because much of it is visceral fat, which is metabolically distinct from subcutaneous fat and influenced by hormones, stress and age. Spot reduction is not possible; the body draws on fat stores according to genetic and hormonal factors.

Belly fat is harder to lose than fat in other areas because a significant proportion of it is visceral fat, a metabolically active type stored deep within the abdominal cavity around the organs, which responds differently to diet and exercise than subcutaneous fat just beneath the skin. Research suggests that visceral fat is associated with greater glucocorticoid activity and different adrenergic signalling compared with subcutaneous depots, which may help explain why chronic stress, poor sleep and hormonal fluctuations are linked to fat accumulation around the middle, even in people who are otherwise active. These associations are well recognised in the clinical literature, though the precise mechanisms continue to be studied.

The body does not allow you to choose where it burns fat from, a concept sometimes called spot reduction. When you create a calorie deficit through diet and exercise, the body draws on fat stores from across the body according to genetic and hormonal factors, not according to which area you exercise most. For many people, the abdomen is one of the last areas to show visible change, which can make progress feel slow even when it is genuinely occurring.

Hormonal changes also play a role. In women, the decline in oestrogen during perimenopause and menopause shifts fat distribution towards the abdomen.^[1] In men, lower testosterone levels are associated with increased visceral fat accumulation.^[2][3] Age-related muscle loss (sarcopenia) further reduces resting metabolic rate, making it easier to gain and harder to lose abdominal fat over time. Understanding these biological factors helps set realistic expectations and underlines why a sustained, whole-body approach is more effective than targeted exercises alone.

What does the NHS recommend for losing belly fat safely?

The NHS recommends a calorie-controlled diet, at least 150 minutes of moderate aerobic activity weekly and strength training on two or more days, with gradual weight loss of 0.5 to 1 kg per week. Waist circumference above 94 cm in men or 80 cm in women signals increased metabolic risk.

The NHS recommends a combination of a balanced, calorie-controlled diet and regular physical activity as the foundation for losing belly fat safely, with no single food, supplement or exercise singled out as a solution. NHS guidance emphasises that losing weight gradually, at a rate of around 0.5 to 1 kg per week, is safer and more sustainable than rapid weight loss, which can lead to muscle loss and nutritional deficiencies.

Waist circumference is used as a clinical marker of metabolic risk. NHS guidance identifies a waist circumference above 94 cm in men or above 80 cm in women as a marker of increased health risk, with thresholds of 102 cm in men and 88 cm in women indicating very high risk.^[4][5] People from some ethnic backgrounds, including South Asian, Chinese, Japanese and Black African or Caribbean communities, face increased health risks at lower waist sizes, and NHS guidance advises that lower thresholds apply for these groups. NICE also recommends considering waist-to-height ratio (aiming for below 0.5) as a complementary measure of central adiposity risk.

In terms of diet, NHS guidance encourages reducing intake of foods high in saturated fat, added sugar and salt, and increasing consumption of vegetables, wholegrains, lean protein and fibre. Fibre in particular supports satiety and helps regulate blood glucose, both of which are relevant to managing abdominal fat. Alcohol is also highlighted as a significant contributor to calorie intake and visceral fat accumulation, and the UK Chief Medical Officers advise keeping consumption to no more than 14 units per week, spread across several days, with several alcohol-free days each week.^[8]

For physical activity, NHS guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week, such as brisk walking or cycling, alongside muscle-strengthening activities on two or more days.^[9][10] Strength training is particularly relevant because building muscle mass increases resting metabolic rate, supporting fat loss over time. The NHS also acknowledges that sleep quality and stress management are important factors in weight control, and may suggest referral to a structured weight management programme for those who need additional support.

Which lifestyle changes actually reduce waist size over time?

Combining a sustained calorie deficit, aerobic exercise, resistance training, seven to nine hours of sleep and stress management produces the greatest reductions in waist circumference. Reducing ultra-processed foods, refined carbohydrates and alcohol has the strongest evidence for reducing visceral fat.

The lifestyle changes with the strongest evidence for reducing waist circumference over time are a sustained calorie deficit achieved through dietary change, regular aerobic exercise, resistance training, improved sleep and active stress management. These work together rather than in isolation, and the evidence consistently shows that combining dietary and physical activity interventions produces greater reductions in waist size than either approach alone.

In terms of diet, reducing ultra-processed foods and refined carbohydrates has been associated with reductions in visceral fat in clinical studies, likely through effects on blood glucose, insulin and overall energy intake. A diet rich in:

• Vegetables and legumes (high in fibre and low in energy density)

• Lean protein such as fish, poultry, eggs and pulses (supports muscle retention during weight loss)

• Wholegrains such as oats, brown rice and wholemeal bread (slower glucose release)

• Healthy unsaturated fats from sources such as olive oil, nuts and avocado

has been associated with reductions in visceral fat in clinical research, including studies of Mediterranean-style dietary patterns. Reducing alcohol intake is also consistently linked to smaller waist measurements. Consistency and overall energy balance remain the primary drivers of fat loss.

For exercise, aerobic activity such as brisk walking, jogging, swimming or cycling directly reduces visceral fat, even when total body weight changes are modest. Resistance training preserves and builds lean muscle, which supports a higher resting metabolic rate. High-intensity interval training (HIIT) has shown promise in systematic reviews for reducing abdominal fat in shorter exercise sessions compared with moderate-intensity continuous training, though any form of regular movement is beneficial.^[11][12]

Evidence from clinical research suggests that short sleep duration is associated with higher levels of cortisol and ghrelin (a hunger hormone), both of which are linked to increased abdominal fat storage.^[15] Aiming for seven to nine hours of quality sleep per night, alongside techniques to manage chronic stress such as mindfulness or talking therapies, supports the hormonal environment associated with fat loss around the middle.

Can medication or medical treatment help with stubborn belly fat?

MHRA-authorised medicines including semaglutide, tirzepatide, liraglutide, orforglipron and orlistat can support clinically meaningful fat loss when used alongside lifestyle changes, for those who meet eligibility criteria. No medicine targets belly fat exclusively; all require individual clinical assessment.

Certain MHRA-authorised medicines can support clinically meaningful reductions in overall body fat, including visceral and abdominal fat, when used alongside dietary and lifestyle changes, though no medication targets belly fat exclusively. Medication is generally considered when lifestyle changes alone have not achieved sufficient weight loss and when a person meets specific clinical criteria. Eligibility thresholds vary by product and are set out in each medicine's SmPC; many licensed weight-management medicines are indicated for adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above (or 27.5 kg/m² or above for some products) in people with at least one weight-related health condition. Prescribing decisions are also guided by NICE technology appraisals and local commissioning arrangements.

Currently licensed options in the UK include, but are not limited to:

• Orlistat (Alli, Xenical): A lipase inhibitor that reduces dietary fat absorption in the gut. Available over the counter at lower dose or on prescription at higher dose. Its mechanism is distinct from the injectable and oral medicines listed below.

• Semaglutide injection (Wegovy): A GLP-1 receptor agonist given as a weekly subcutaneous injection, licensed for chronic weight management. The MHRA has authorised doses up to 2.4 mg weekly, and a higher 7.2 mg strength has also received MHRA authorisation. An oral formulation (Wegovy 25 mg tablets) is also licensed in the UK for weight management, with a different dosing schedule.^[17][18] Clinical trials have demonstrated significant reductions in waist circumference alongside overall weight loss.

• Liraglutide (Saxenda): A GLP-1 receptor agonist given as a daily subcutaneous injection, licensed for weight management.

• Tirzepatide (Mounjaro): A dual GIP and GLP-1 receptor agonist, MHRA-authorised for both type 2 diabetes and chronic weight management. It is administered as a weekly injection using a multiple-dose KwikPen.

• Orforglipron (Foundayo): An oral GLP-1 receptor agonist that has received a UK licence for weight management. It is taken as a daily tablet.

The injectable and oral GLP-1 and GIP/GLP-1 receptor agonists listed above work primarily by reducing appetite, slowing gastric emptying and improving metabolic signalling. Orlistat works differently, by inhibiting the enzyme lipase in the gut to reduce fat absorption. All of these medicines require a clinical assessment and are not suitable for everyone. If you experience suspected side effects from any medicine, you can report these to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Bolt Pharmacy is a GPhC-registered online pharmacy offering weight-management consultations, with prescriber review and pharmacist support. Medicines such as those listed above are only prescribed where a prescriber considers them clinically appropriate following individual assessment.

Bariatric surgery remains the most effective intervention for severe obesity and produces the greatest reductions in visceral fat, but it is reserved for people who meet strict clinical criteria and is commissioned by Integrated Care Boards (ICBs) on a case-by-case basis.

How long does it realistically take to see results around your middle?

Most people notice measurable reductions in waist circumference within eight to twelve weeks of consistent dietary and lifestyle changes. Monthly waist measurements at the midpoint between the lower rib and hip bone are more reliable than daily weighing for tracking abdominal fat loss.

Most people who make consistent dietary and lifestyle changes begin to notice measurable reductions in waist circumference within eight to twelve weeks, though the timeline varies considerably depending on starting weight, age, hormonal status, adherence and the specific changes made. Visceral fat, despite being harder to shift initially, is generally considered more metabolically responsive than subcutaneous fat once a sustained calorie deficit is established, meaning it can reduce meaningfully even before visible changes in body shape become obvious.

A useful way to track progress is to measure waist circumference rather than relying solely on the scales. Body weight can fluctuate day to day due to fluid retention, hormonal cycles and digestive contents, whereas a monthly waist measurement taken at the midpoint between the lower rib and the top of the hip bone gives a more reliable picture of abdominal fat change over time. NHS guidance provides instructions on correct measurement technique. The NHS uses waist circumference as a clinical marker of metabolic risk, so tracking it has practical health value beyond aesthetics.

For people using MHRA-authorised weight management medicines, data from pivotal clinical trials show that meaningful reductions in waist circumference typically become apparent within the first three to six months of treatment, with continued improvement over twelve months or longer when treatment is maintained alongside lifestyle changes.^[24][25] Results vary between individuals, and medicines are not a substitute for dietary and behavioural change.

It is worth speaking to your GP if you are concerned about rapid or unexplained changes in abdominal girth, or if you have tried lifestyle changes for several months without success. Your GP can assess for underlying conditions such as polycystic ovary syndrome, hypothyroidism or Cushing's syndrome, which can contribute to abdominal weight gain and may require specific treatment. It is also worth discussing with your GP whether any medicines you take regularly, such as corticosteroids or certain antipsychotics, may be contributing to weight gain around the middle. Seek urgent medical attention if you develop sudden, severe abdominal pain, rapidly progressive abdominal distension with breathlessness or jaundice, fever with vomiting, or any signs of gastrointestinal bleeding. Contact NHS 111 if you are unsure whether your symptoms need urgent assessment.

Scientific References

1. Perimenopause and metabolic vulnerability: hormones, body composition and lifestyle changes.
2. Low testosterone is a phenotype of visceral adiposity.
3. The association between androgenic profile and cardiometabolic risk factors in young men: insights from a large observational cohort study.
4. Overweight and obesity in adults.
5. Waist circumference as a measure for indicating need for weight management (Lean et al., 1995).
6. Overweight and obesity management (NG246) – Identifying and assessing overweight, obesity and central adiposity.
7. Calculate your waist to height ratio.
8. Alcohol consumption: advice on low risk drinking (UK CMO guidelines).
9. Physical activity guidelines for adults aged 19 to 64.
10. New UK CMO activity guidelines show every movement counts.
11. Efficacy of Interval Training in Improving Body Composition and Adiposity in Apparently Healthy Adults: An Umbrella Review with Meta-Analysis.
12. Comparative Efficacy of Exercise Type on Visceral Adipose Tissue in Patients With Prediabetes and Type 2 Diabetes Mellitus: A Systematic Review With Pairwise and Network Meta-Analyses.
13. Effect of low-volume interval training on whole-body, abdominal and visceral fat in adults living with overweight and obesity: A systematic review and meta-analysis.
14. Effect of High-Intensity Interval Training on Total, Abdominal and Visceral Fat Mass (Maillard et al., 2018).
15. Short sleep duration is associated with reduced leptin and elevated ghrelin (Taheri et al., 2004).
16. Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity.
17. First GLP-1 tablet for weight loss approved in the UK (oral semaglutide / Wegovy 25 mg tablets).
18. Wegovy 25 mg tablets – Summary of Product Characteristics.
19. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
20. Four-dose Mounjaro KwikPen approved by MHRA for diabetes and weight management.
21. UK first in Europe to authorise orforglipron (Foundayo) for weight management and type 2 diabetes.
22. New oral GLP-1 medicine for weight management and type 2 diabetes (Foundayo / orforglipron).
23. Overweight and obesity management (NG246) – Medicine options for weight management in adults.
24. Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., 2021).
25. Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.
26. Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials.
27. Seven GLP-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis.

Frequently Asked Questions